Drug Search Results
More Filters [+]

INVAC-1

Alternative Names: INVAC-1, INVAC1
Latest Update: 2021-05-31
Latest Update Note: Clinical Trial Update

Product Description

INVAC-1 is a DNA plasmid encoding a modified human telomerase reverse transcriptase (hTERT) protein devoid of catalytic activity. (Sourced from: https://aacrjournals.org/clincancerres/article/26/3/588/83062/A-First-in-Human-Phase-I-Study-of-INVAC-1-an)

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Invectys
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for INVAC-1

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia

Phase 1: Oncology Solid Tumor Unspecified|Oncology Hematological Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT02301754

P1

Completed

Oncology Solid Tumor Unspecified

2020-12-19

30%

INVAC1-CT-201

P2

Terminated

Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia

2020-06-30

55%

INVAC1-CT-101

P1

Completed

Oncology Solid Tumor Unspecified|Oncology Hematological Unspecified

2018-02-01

Recent News Events